The Erectile Dysfunction drugs in development market research report provides comprehensive information on the therapeutics under development for Erectile Dysfunction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Erectile Dysfunction. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Erectile Dysfunction and features dormant and discontinued products.

GlobalData tracks 46 drugs in development for Erectile Dysfunction by 43 companies/universities/institutes. The top development phase for Erectile Dysfunction is preclinical with 15 drugs in that stage. The Erectile Dysfunction pipeline has 42 drugs in development by companies and four by universities/ institutes. Some of the companies in the Erectile Dysfunction pipeline products market are: NAL Pharmaceuticals, Initiator Pharma and Shanghai Institute of Materia Medica Chinese Academy of Sciences.

The key targets in the Erectile Dysfunction pipeline products market include cGMP Specific 3′,5′ Cyclic Phosphodiesterase (cGMP Binding cGMP Specific Phosphodiesterase or PDE5 or PDE5A or EC 3.1.4.35), Sodium Dependent Dopamine Transporter (DA Transporter or DAT or Solute Carrier Family 6 Member 3 or SLC6A3), and Sodium Dependent Serotonin Transporter (5HT Transporter or 5HTT or Solute Carrier Family 6 Member 4 or SLC6A4).

The key mechanisms of action in the Erectile Dysfunction pipeline product include cGMP Specific 3′,5′ Cyclic Phosphodiesterase (cGMP Binding cGMP Specific Phosphodiesterase or PDE5 or PDE5A or EC 3.1.4.35) Inhibitor with 22 drugs in Pre-Registration. The Erectile Dysfunction pipeline products include eight routes of administration with the top ROA being Oral and seven key molecule types in the Erectile Dysfunction pipeline products market including Small Molecule, and Cell Therapy.

Erectile Dysfunction overview

Erectile dysfunction (ED) is the inability of a man to have an erection hard enough to have sexual intercourse. It is also known as impotence. The predisposing factors include tobacco usage, overweight, injuries, drug and alcohol use, and medications including antidepressants, antihistamines, and medications to treat high blood pressure, pain, or prostate cancer.

For a complete picture of Erectile Dysfunction’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.